Objective As genotyping technology has progressed, genome-wide association studies
(GWAS) have matured into efficient and effective tools for mapping genes underlying human …

Regarding weight gain, most promising and most consistent findings were obtained in the
serotonergic system (HTR2C) and with hypothalamic leptin–melanocortin genes, in …

Tardive dyskinesia (TD) is an involuntary movement disorder that can occur in up to 25% of
patients receiving long-term first-generation antipsychotic treatment. Its etiology is unclear …

The mapping of the human genome and subsequent advancements in genetic technology
had provided clinicians and scientists an understanding of the genetic basis of altered drug …

Objective To examine the unique and congruent findings between multiple raters in a
genome-wide association study (GWAS) in the context of understanding individual …

We implemented a two-step approach to detect potential predictor gene variants for
neuroleptic-induced tardive dyskinesia (TD) in schizophrenic subjects. First, we screened …

The in vivo labeling and brain imaging of dopamine transporters measure the density of
dopamine neuron terminals in the human caudate/putamen. A review of such studies shows …

Objective Overactivity of dopaminergic neurotransmission is a putative mechanism of tardive
dyskinesia (TD). Dopamine beta‐hydroxylase (DBH) is a key enzyme in the conversion of …

Only a subset of patients will typically respond to any given prescribed drug. The time it
takes clinicians to declare a treatment ineffective leaves the patient in an impaired state and …

Schizophrenia is a debilitating disorder that occurs the world over. Although antipsychotics
are largely effective in treating the positive symptoms of schizophrenia, the outcomes are …